Private Markets Analyst, pvtIQ

Beier Luo

Private Markets Analyst

Private Markets Research and Data, Reimagined

pvtIQ

pvtIQ leverages Smartkarma’s technology and distribution to deliver high-quality research and data on Asian private markets.

Private Capital Markets

Doctor Anywhere / Private Capital Markets

<h2>Executive Summary</h2><ul><li><strong>Regional Omnichannel Healthcare Platform:</strong> Doctor Anywhere operates a hybrid medical model across five Southeast Asian markets, integrating a digital telemedicine application with a physical network of clinics and specialist centres. The company serves over three million registered users, providing a single touchpoint that bridges virtual consultations with in-person diagnostic care.</li><li><strong>Strong Institutional Capital Support:</strong> The company has secured approximately US$176.0m in total funding from top-tier strategic and financial investors, including a US$40.8m Series C extension in late 2023. This capital supports a closed-loop business model that leverages corporate and insurance partnerships for efficient user acquisition while cross-selling higher-margin physical medical services.</li><li><strong>Profitability Inflection From Cost Discipline, Not Growth: </strong>FY2025 delivered the company's first operating profit in four years, at a margin of roughly 1%, achieved through the Vietnam exit, the wind-down of underperforming units and headcount reduction rather than volume expansion. The company remains net loss-making, the physical clinic network continues to carry material fixed costs, and no new primary capital has been raised since December 2023. The central question is whether a margin bought through rationalisation can be sustained and widened once the one-off cost actions are exhausted.</li></ul>

Executive SummaryRegional Omnichannel Healthcare Platform: Doctor Anywhere operates a hybrid medical model across five Southeast Asian markets, integrating a digital telemedicine application with a physical network of clinics and specialist centres. The company serves over three million registered users, providing a single touchpoint that bridges virtual consultations with in-person diagnostic care.Strong Institutional Capital Support: The company has secured approximately US$176.0m in total funding from top-tier strategic and financial investors, including a US$40.8m Series C extension in late 2023. This capital supports a closed-loop business model that leverages corporate and insurance partnerships for efficient user acquisition while cross-selling higher-margin physical medical services.Profitability Inflection From Cost Discipline, Not Growth: FY2025 delivered the company's first operating profit in four years, at a margin of roughly 1%, achieved through the Vietnam exit, the wind-down of underperforming units and headcount reduction rather than volume expansion. The company remains net loss-making, the physical clinic network continues to carry material fixed costs, and no new primary capital has been raised since December 2023. The central question is whether a margin bought through rationalisation can be sustained and widened once the one-off cost actions are exhausted.

Doctor Anywhere: From Telehealth App to Integrated Regional Provider (Initiation)

Research from Tech in Asia, Tech in Asia

Tech in Asia

Research from Tech in Asia

Tech in Asia (YC W15) is the largest English-language technology media company that focuses on Asia. From the latest news to the hottest trends and the boldest startups to the strongest titans, we cover everything tech in the region. Our goal is to build and serve Asia’s tech and startup community.

News from Tech in Asia

<ul><li>Singapore-headquartered <a href="https://doctoranywhere.com/" target="_blank" rel="noopener">Doctor Anywhere</a> (DA) is set to acquire medical services group <a href="https://asianhealthcare.com.sg/" target="_blank" rel="noopener">Asian Healthcare Specialists</a> (AHS) in a cash deal valued at about S$109 million (US$76.7 million) at an offer price of S$0.188 (US$0.13) per share.</li><li>The healthtech firm has also announced a US$38.8 million series C1 financing round led by Novo Holdings to partly fund the AHS acquisition and accelerate growth.</li><li>According to DA’s financial statements, the company’s revenue hit S$31.9 million in 2021, an over 2.8x growth from the previous year</li></ul>

Singapore-headquartered Doctor Anywhere (DA) is set to acquire medical services group Asian Healthcare Specialists (AHS) in a cash deal valued at about S$109 million (US$76.7 million) at an offer price of S$0.188 (US$0.13) per share.The healthtech firm has also announced a US$38.8 million series C1 financing round led by Novo Holdings to partly fund the AHS acquisition and accelerate growth.According to DA’s financial statements, the company’s revenue hit S$31.9 million in 2021, an over 2.8x growth from the previous year

Doctor Anywhere Acquires SG Healthcare Provider, Nets $38.8m Funding

Singapore

Doctor Anywhere Pte. Ltd. operates as a telehealth company. The Company offers health care accessibility through video consultations on its mobile application. Doctor Anywhere serves customers in Singapore.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Doctor Anywhere (1632166D SP)

Doctor Anywhere: From Telehealth App to Integrated Regional Provider (Initiation)

Executive Summary Omnichannel Regional Healthcare Ecosystem: Doctor Anywhere operates a hybrid healthcare platform serving over 3.0 million...

pvtIQ

Doctor Anywhere Acquires SG Healthcare Provider, Nets $38.8m Funding

Singapore-headquartered Doctor Anywhere (DA) is set to acquire medical services group Asian Healthcare Specialists (AHS) in a cash deal valued at...

Tech in Asia

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)